Topotecan is active against Wilms' tumor: Results of a multi-institutional phase II study

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3130-3136

  Metzger, Monika L ^a   Stewart, Clinton F ^a   Freeman III, Burgess B ^a   Billups, Catherine A ^a   Hoffer, Fredric A ^a   Wu, Jianrong ^a   Coppes, Max J ^a   Grant, Ronald ^a   Chintagumpala, Murali ^a   Mullen, Elizabeth A ^a   Alvarado, Carlos ^a   Daw, Najat C ^a   Dome, Jeffrey S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; COTRIMOXAZOLE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; ILEUS; INFECTION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROBLASTOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TYPHLITIS; VOMITING;

AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME; WILMS TUMOR;

EID: 34547679585     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.9298     Document Type: Article

References (38)

1. Dome JS, Liu T, Krasin M, et al: Improved survival for patients with recurrent Wilms tumor: The experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 24:192-198, 2002
2. Dome JS, Cotton CA, Perlman EJ, et al: Treatment of anaplastic histology Wilms' tumor: Results from the Fifth National Wilms' Tumor Study. J Clin Oncol 24:2352-2358, 2006
3. Green DM, Beckwith JB, Breslow NE, et al: Treatment of children with stages II to IV anaplastic Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 12:2126-2131, 1994
4. Garaventa A, Hartmann O, Bernard JL, et al: Autologous bone marrow transplantation for pediatric Wilms' tumor: The experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 22:11-14, 1994
5. Pein F, Michon J, Valteau-Couanet D, et al: High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: A French Society of Pediatric Oncology study. J Clin Oncol 16:3295-3301, 1998
6. Campbell AD, Cohn SL, Reynolds M, et al: Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: The experience at Children's Memorial Hospital. J Clin Oncol 22:2885-2890, 2004
7. Green DM, Cotton CA, Malogolowkin M, et al: Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 48:493-499, 2007
8. Grundy P, Breslow N, Green DM, et al: Prognostic factors for children with recurrent Wilms' tumor: Results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 7:638-647, 1989
9. Kremens B, Gruhn B, Klingebiel T, et al: High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 30:893-898, 2002
10. Malogolowkin MH, Green DM, Cotton C, et al: Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D and doxorubicin: A report from the National Wilms Tumor Study (NWTS) Group. J Clin Oncol 23:801s, 2005 (suppl 16s, abstr 8507)
11. Bomgaars L, Berg SL, Blaney SM: The development of camptothecin analogs in childhood cancers. Oncologist 6:506-516, 2001
12. Pappo AS, Lyden E, Breneman J, et al: Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study. J Clin Oncol 19:213-219, 2001
13. Stewart CF, Iacono LC, Chintagumpala M, et al: Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 22:3357-3365, 2004
14. Nitschke R, Parkhurst J, Sullivan J, et al: Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318, 1998
15. Santana VM, Furman WL, Billups CA, et al: Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039-4047, 2005
16. Tubergen DG, Stewart CF, Pratt CB, et al: Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:352-361, 1996
17. Houghton PJ, Stewart CF, Zamboni WC, et al: Schedule-dependent efficacy of camptothecins in models of human cancer. Ann N Y Acad Sci 803:188-201, 1996
18. Dome JS, Neale G, Hill DA, et al: Anti-tumor activity of topotecan against Wilms tumor: Translation of a xenograft model to a phase II study. Pediatr Blood Cancer 45:432-433, 2005
19. Santana VM, Zamboni WC, Kirstein MN, et al: A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633-640, 2003
20. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
21. Zamboni WC, Houghton PJ, Johnson RK, et al: Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284:89-94, 1998
22. D'Argenio DZ, Schumitzky A, Wolf W: Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Comput Methods Programs Biomed 27:47-54, 1988
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Tan M, Xiong X: Continuous and group sequential conditional probability ratio tests for phase II clinical trials. Stat Med 15:2037-2051, 1996
25. Zamboni WC, Bowman LC, Tan M, et al: Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 43:454-460, 1999
26. Pinkerton CR, Pritchard J: A phase II study of ifosfamide in paediatric solid tumours. Cancer Chemother Pharmacol 24:S13-S15, 1989 (suppl 1)
27. Tournade MF, Lemerle J, Brunat-Mentigny M, et al: Ifosfamide is an active drug in Wilms' tumor: A phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol 6:793-796, 1988
28. Tournade MF: A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor. Cancer Chemother Pharmacol 24:S31-S33, 1989 (suppl 1)
29. Pein F, Pinkerton R, Tournade MF, et al: Etoposide in relapsed or refractory Wilms' tumor: A phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 11:1478-1481, 1993
30. de Camargo B, Melaragno R, Saba e Silva N, et al: Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: Experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol 22:258-260, 1994
31. Ragab AH, Sutow WW, Komp DM, et al: Adriamycin in the treatment of childhood solid tumors: A Southwest Oncology Group study. Cancer 36:1567-1576, 1975
32. Pratt CB, Stewart C, Santana VM, et al: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539-543, 1994
33. Reid RJ, Benedetti P, Bjornsti MA: Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta 1400:289-300, 1998
34. Tanizawa A, Beitrand R, Kohlhagen G, et al: Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 268:25463-25468, 1993
35. McLeod HL, Keith WN: Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74:508-512, 1996
36. Saleem A, Ibrahim N, Patel M, et al: Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res 57:5100-5106, 1997
37. Woessner RD, Eng WK, Hofmann GA, et al: Camptothecin hyper-resistant P388 cells: Drug-dependent reduction in topoisomerase I content. Oncol Res 4:481-488, 1992
38. Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992